13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • CA209-7DX

    Acronym: 

    CheckMate 7 DX

    ACTRN/NCT /ethics: 

    NCT04100018

    Scientific title: 

    A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

    Summary of trial and patient characteristics

    Cancer Type
    Trial Type
    Phase Tumour Stream Prostate
    Age Range 18 years and older Cancer Stage
    Sex Male Anticipated Start Date 2019-12-16
    Molecular Target Anticipated End Date 2024-05-14
    Cancer Type
    Trial Type
    Phase
    Age Range 18 years and older
    Sex Male
    Molecular Target
    Tumour Stream Prostate
    Cancer Stage
    Anticipated Start Date 2019-12-16
    Anticipated End Date 2024-05-14

    Trial Summary

    The purpose of this study is to test the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation

    Lay Summary

    A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

    Sponsor / Cooperative group

    Bristal_Myers Squibb

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Calvary North Adelaide Hospital Julie Rowe julie.rowe@calvarycare.org.au 08 8239 9536 Not Yet Recruiting